From Seeking Alpha:
“The biotech sector is likely in store for a wave of consolidation. While the above mentioned big pharma companies have boosted their pipelines and created massive biopharma companies with their acquisitions, there are still many pharmaceutical companies that desperately need to fill their pipelines.
And that bodes well for biotech—particularly when you consider Read more »
The Chinese biotech market is developing rapidly, offering great potential for providing future innovation, novel drugs and partnering opportunities. To help unlock this potential for the mutual benefit of homegrown Chinese biotechs and international firms, EBD Group and ChinaBio® LLC have announced their new partnering event, ChinaBio® Partnering Forum, to be held June 23–24, 2009 Read more »
Reviewing the Rexahn Pharmaceuticals pipeline is like reading about a team of potential medal winning Olympic athletes. Each compound is an innovative or first in class product in its therapeutic segment. Three drugs are currently in Phase II clinical trials to treat cancers, central nervous system disorders, and sexual dysfunction. Further, IND filings for two Read more »
A rare find among partnering candidates at BIO-Europe Spring® is Kenta Biotech offering late stage development opportunity for a family of four complementary antibodies targeting the most difficult to treat hospital infections, a market yet untouched by antibody therapies. The lead product is in Phase IIA for treatment of nosocomial pneumonia. The deal includes a Read more »
It doesn’t feel like it now, but biotech’s Golden Age is upon us.
Patent expirations are on the verge of creating giant gaps in the revenue streams at the big pharma houses. The problem is a pandemic affecting all of the old-line drug makers, and the megamerger approach of combining companies that suffer from the same Read more »
The financial news site Seeking Alpha reports Leerink Swann’s research now postulating “partnerships and acquisitions”:
“Forget about mergers and acquisitions (M&A). Think about partnerships and acquisitions or what Leerink Swann (LS), which specializes in healthcare stock coverage, is calling “P&A.”
In a research note to clients today, the LS team says there’s a “perfect storm” for Read more »
A recent GEN roundtable offers some interesting perspectives on surviving the economic turmoil. Given the international nature of next week’s BIO-Europe Spring® partnering meeting, this commentary rings true:
“…management teams need to develop globally integrated strategies with a more complete and perhaps a bit bolder vision of the way the world may evolve over the horizon Read more »
This year’s BIO-Europe Spring® conference has two sessions devoted to the topic of personalized medicine, “Personalized Medicine — The Next Big Thing in Biotech? (Monday, March 16, 11:30–12:30) and “How Personalized Medicine will Change the Economics of Healthcare” (Monday, March 16, 17:15–18:15).
These session titles provide hints of caution about the future of personalized medicine, Read more »
Newsletter